SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F

Description

Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 15.37 Billion
Market Size 2030	USD 21.44 Billion
CAGR 2025-2030	5.90%
Fastest Growing Segment	Jardiance
Largest Market	North America

Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.

Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.

Key Market Challenges

High Cost of Therapy

One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.

The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.

Key Market Trends

Rising Prevalence of Diabetes

The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.

Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.

Key Market Players

Boehringer Ingelheim International GmbH
AstraZeneca
Merck & Co., Inc.
Janssen Pharmaceuticals, Inc.
TheracosBio, LLC
Lexicon Pharmaceuticals, Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

SGLT2 Inhibitors Market, By Drug:

Jardiance
Farmiga
Inpefa
Invokana
Others

SGLT2 Inhibitors Market, By Indication:

Type 2 Diabetes
Cardiovascular
Others

SGLT2 Inhibitors Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.

Available Customizations:

Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global SGLT2 Inhibitors Market

5. Global SGLT2 Inhibitors Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others)
- 5.2.2. By Indication (Type 2 Diabetes, Cardiovascular, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America SGLT2 Inhibitors Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug
- 6.2.2. By Indication
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States SGLT2 Inhibitors Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug
    - 6.3.1.2.2. By Indication
- 6.3.2. Mexico SGLT2 Inhibitors Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug
    - 6.3.2.2.2. By Indication
- 6.3.3. Canada SGLT2 Inhibitors Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug
    - 6.3.3.2.2. By Indication

7. Europe SGLT2 Inhibitors Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug
- 7.2.2. By Indication
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. France SGLT2 Inhibitors Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug
    - 7.3.1.2.2. By Indication
- 7.3.2. Germany SGLT2 Inhibitors Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug
    - 7.3.2.2.2. By Indication
- 7.3.3. United Kingdom SGLT2 Inhibitors Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Drug
    - 7.3.3.2.2. By Indication
- 7.3.4. Italy SGLT2 Inhibitors Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug
    - 7.3.4.2.2. By Indication
- 7.3.5. Spain SGLT2 Inhibitors Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug
    - 7.3.5.2.2. By Indication

8. Asia Pacific SGLT2 Inhibitors Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug
- 8.2.2. By Indication
- 8.2.3. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China SGLT2 Inhibitors Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug
    - 8.3.1.2.2. By Indication
- 8.3.2. India SGLT2 Inhibitors Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug
    - 8.3.2.2.2. By Indication
- 8.3.3. South Korea SGLT2 Inhibitors Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug
    - 8.3.3.2.2. By Indication
- 8.3.4. Japan SGLT2 Inhibitors Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug
    - 8.3.4.2.2. By Indication
- 8.3.5. Australia SGLT2 Inhibitors Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug
    - 8.3.5.2.2. By Indication

9. South America SGLT2 Inhibitors Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug
- 9.2.2. By Indication
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil SGLT2 Inhibitors Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug
    - 9.3.1.2.2. By Indication
- 9.3.2. Argentina SGLT2 Inhibitors Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug
    - 9.3.2.2.2. By Indication
- 9.3.3. Colombia SGLT2 Inhibitors Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug
    - 9.3.3.2.2. By Indication

10. Middle East and Africa SGLT2 Inhibitors Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug
- 10.2.2. By Indication
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa SGLT2 Inhibitors Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug
    - 10.3.1.2.2. By Indication
- 10.3.2. Saudi Arabia SGLT2 Inhibitors Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug
    - 10.3.2.2.2. By Indication
- 10.3.3. UAE SGLT2 Inhibitors Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug
    - 10.3.3.2.2. By Indication

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global SGLT2 Inhibitors Market: SWOT Analysis

15. Porters Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Boehringer Ingelheim International GmbH
- 16.1.1. Business Overview
- 16.1.2. Company Snapshot
- 16.1.3. Products & Services
- 16.1.4. Financials (As Reported)
- 16.1.5. Recent Developments
- 16.1.6. Key Personnel Details
- 16.1.7. SWOT Analysis
16.2. AstraZeneca
16.3. Merck & Co., Inc.
16.4. Janssen Pharmaceuticals, Inc.
16.5. TheracosBio, LLC
16.6. Lexicon Pharmaceuticals, Inc.
16.7. Eli Lilly and Company
16.8. Bristol-Myers Squibb Company
16.9. Glenmark Pharmaceuticals Ltd.